Migraine Often Improves Over Long Term

BY MICHELE G. SULLIVAN
Mid-Atlantic Bureau

CHICAGO — Migraine appears to have a favorable long-term prognosis in many patients, with more than a third experiencing cessation of headache and the vast majority of persistent migraineurs reporting symptom improvement over 12 years.

“These data probably reflect the natural course of migraine disease,” Dr. Carl Dahlöf said at the annual meeting of the American Headache Society. “They also probably suggest that we are doing a better job with the newer drugs, and appear to be preventing episodic migraineurs from developing chronic migraine.”

Dr. Dahlöf of the Göteborg (Sweden) Migraine Clinic presented 12 years of follow-up data obtained on 374 patients diagnosed with migraine before 1996. The group included 200 men and 174 women, a ratio that does not reflect the gender balance seen in any headache practice, Dr. Dahlöf noted. “We chose equal numbers of men and women because we wanted to see if there were any gender differences in progression or improvement over the years.”

All patients participated in a telephone survey that assessed the changing pattern of their migraine from 1994 to 2006.

Over the follow-up period, 29% of patients (37 women and 33 men) reported that their migraines had ceased. For women, migraine without aura was the absence of hereditary factors, and the absence of aggravation from physical activity appeared to predict cessation. For men, the apparent predictors were a nonthrob- bing migraine, and the absence of nausea and sensitivity to smells.

“Surprisingly, we also found in men that smoking and lack of alcohol as a trigger factor were also predictors,” Dr. Dahlöf said. “We had expected that more frequent or severe migraine would predict progression, but we did not find this as true.”

The remaining 264 patients continued to experience migraine, but the majority reported at least some improvement of their symptoms over time.

In all, 80% reported a change in headache frequency, with 80% of these saying they had fewer attacks per month.

More than half of persistent migraineurs reported a change in duration of headache, with 66% saying their attacks had grown shorter. In terms of severity, 66% of migraineurs reported a change in pain intensity over time, with most of this group (84%) reporting milder pain.

Of the entire group of 374 patients, only six (1.6%) developed chronic migraine, a number that is vastly smaller than the annual transformation rate reported in many studies, Dr. Dahlöf said.

Despite the changing pattern of migraine, a significant proportion of migraineurs continued to experience impairment in their quality of life, including decreased family and social functioning, and absence from work.

Few Migraineurs Use Emergency Department

BY ALICIA AULT
Associate Editor, Practice Trends

CHICAGO — Headache is the fifth most common emergency department complaint, but only a small percentage of migraineurs use emergency care for treatment, according to an analysis of the American Migraine Prevalence and Prevention study presented at the annual meeting of the American Headache Society.

Dr. Benjamin Friedman of the Albert Einstein College of Medicine, New York, said he and his colleagues sought to determine how often Americans with headache use the ED or an urgent care facility, and what the risk factors were for frequent use.

The goal of the study was to discern ways to prevent urgent headache visits. Currently there are about 3 million visits a year for headache, he said.

The American Migraine Prevalence and Prevention study (AMPP) is an ongoing multisite survey that began in 2004 when a self-administered headache questionnaire was mailed to a random sample of 120,000 households. The study was supported by a grant to the National Headache Foundation from Ortho-McNeil Inc. Of the 162,576 individuals who responded, 30,721 self-reported severe headaches. Dr. Friedman and his colleagues mailed a follow-up survey in 2005 to a random subsample of 24,000 of the headache sufferers, asking for data on emergency or urgent care use within the previous 12 months.

NEW SEROQUEL XR

In patients with schizophrenia

• SEROQUEL XR has proven efficacy and broad symptom improvement
• During titration in the first week, SEROQUEL XR was generally well tolerated*

Important Safety Information

• SEROQUEL XR is indicated for the treatment of schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response

• Elderly patients with dementia-related psychosis treated with atypical antipsychotics are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis (see Boxed Warning)

• Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, includingquetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse events in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing

• A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with administration of antipsychotic drugs, including quetiapine. The syndrome may include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs

*Data combined from 2 multicenter, 6-week, randomized, double-blind, placebo-controlled schizophrenia trials comparing SEROQUEL XR (670 mg to placebo [n=230]). The incidence of somnolence was 9.0% vs 1.3% for placebo, sedation was 7.4% vs 3.4% for placebo, dizziness was 5.9% vs 2.6% for placebo, dry mouth was 6.8% vs 0.9% for placebo, headache was 3.4% vs 6.4% for placebo, and insomnia was 2.8% vs 7.2% for placebo.

Please see Brief Summary of Prescribing Information, including Boxed Warning, on adjacent pages.